Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin
Randomized, Dose-Ranging, Cross-over, Placebo-controlled Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin
Sponsor: Boston Therapeutics
Listed as NCT02135549, this NA trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Boston Therapeutics, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Mar 2018 — Jun 2018 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Mar 2018 [monthly]
Completed NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .